Formulation Fundamentals
The development of injectable peptide formulations requires careful consideration of multiple physicochemical parameters to ensure stability, bioavailability, and patient tolerability in research applications.
pH Optimization
Most peptides demonstrate optimal stability within narrow pH ranges. Formulation development typically involves pH screening across a range of 4.0–8.0 using buffers including:
- —Phosphate buffer: pH 6.0–8.0, widely used for parenteral formulations
- —Acetate buffer: pH 4.0–5.5, suitable for acid-stable peptides
- —Histidine buffer: pH 5.5–7.0, increasingly preferred for biologics due to cryoprotective properties
Excipient Selection
40+
Excipients GRAS-listed for use in injectable pharmaceutical formulations
Stabilizers
- —Trehalose and sucrose: Primary cryoprotectants for lyophilized formulations (typically 5–10% w/v)
- —Human serum albumin: Carrier protein preventing surface adsorption
- —Polysorbate 20/80: Surfactant preventing aggregation (0.01–0.1% w/v)
Tonicity Agents
Injectable formulations require isotonicity (approximately 285–310 mOsm/kg). Common tonicity agents include sodium chloride (0.9% w/v) and mannitol (5% w/v).
Advanced Delivery Systems
Emerging delivery technologies for peptide compounds include:
Microsphere Systems
Poly(lactic-co-glycolic acid) (PLGA) microspheres enable controlled release over days to weeks, reducing administration frequency in research protocols.
Lipid Nanoparticles
Lipid nanoparticle (LNP) encapsulation protects peptides from enzymatic degradation and can be engineered for targeted tissue delivery.
Quality Control Parameters
Critical quality attributes for injectable peptide formulations:
- —Purity: ≥98% by RP-HPLC
- —Endotoxin: <1 EU/mg by LAL assay
- —Particulate matter: USP <787> compliance
- —pH: ±0.2 of target specification
- —Osmolality: 285–310 mOsm/kg